Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
13
PTHS Quote, Financials, Valuation and Earnings
Last price:
$26.92
Seasonality move
:
225.3%
Day range:
$24.21 - $27.07
52-week range:
$5.62 - $54.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.07x
P/B ratio:
0.30x
Volume:
34.3K
Avg. volume:
28.8K
1-year change:
301.97%
Market cap:
$17.5M
Revenue:
--
EPS (TTM):
-$14.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PTHS
Pelthos Therapeutics, Inc.
|
$4.4M | -$0.58 | -- | -22.76% | $59.80 |
|
AGEN
Agenus, Inc.
|
$80.4M | $2.20 | 144.6% | -70.59% | $12.33 |
|
GNPX
Genprex, Inc.
|
-- | -$0.41 | -- | -89.71% | $7.50 |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$58.1M | $1.89 | 29.32% | -74.47% | $237.50 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
|
TVTX
Travere Therapeutics, Inc.
|
$133.5M | $0.07 | 91.27% | -87.94% | $41.5000 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PTHS
Pelthos Therapeutics, Inc.
|
$26.57 | $59.80 | $17.5M | -- | $0.00 | 0% | 9.07x |
|
AGEN
Agenus, Inc.
|
$3.93 | $12.33 | $133.7M | -- | $0.00 | 0% | 0.99x |
|
GNPX
Genprex, Inc.
|
$3.36 | $7.50 | $3.4M | -- | $0.00 | 0% | -- |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$184.87 | $237.50 | $3.6B | 88.98x | $0.00 | 0% | 14.48x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.73 | $11.00 | $139.1M | 24.89x | $0.00 | 0% | 2.20x |
|
TVTX
Travere Therapeutics, Inc.
|
$35.0000 | $41.5000 | $3.1B | -- | $0.00 | 0% | 7.29x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PTHS
Pelthos Therapeutics, Inc.
|
5.64% | 7.137 | 18.84% | 0.90x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.383 | 285.06% | 0.03x |
|
GNPX
Genprex, Inc.
|
-- | 2.374 | -- | 0.43x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
32.19% | 1.626 | 12.95% | 23.64x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
|
TVTX
Travere Therapeutics, Inc.
|
81.76% | 1.077 | 15.42% | 2.50x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PTHS
Pelthos Therapeutics, Inc.
|
$4M | -$15.4M | -192.61% | -241.95% | -207.43% | -$15.3M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
GNPX
Genprex, Inc.
|
-- | -$3.3M | -900.4% | -900.4% | -- | -$3.2M |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$103.6M | $54.1M | 5.15% | 5.72% | 46.85% | $4.8M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
|
TVTX
Travere Therapeutics, Inc.
|
$147.5M | $24.9M | -21.07% | -263.9% | 15.12% | -$871K |
Pelthos Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PTHS or AGEN?
Agenus, Inc. has a net margin of -219.26% compared to Pelthos Therapeutics, Inc.'s net margin of -116.82%. Pelthos Therapeutics, Inc.'s return on equity of -241.95% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PTHSPelthos Therapeutics, Inc.54.31% -$5.30 $61.7M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About PTHS or AGEN?
Pelthos Therapeutics, Inc. has a consensus price target of $59.80, signalling upside risk potential of 125.07%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 213.83%. Given that Agenus, Inc. has higher upside potential than Pelthos Therapeutics, Inc., analysts believe Agenus, Inc. is more attractive than Pelthos Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTHSPelthos Therapeutics, Inc.5 0 0 AGENAgenus, Inc.2 1 0 -
Is PTHS or AGEN More Risky?
Pelthos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.01%.
-
Which is a Better Dividend Stock PTHS or AGEN?
Pelthos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pelthos Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTHS or AGEN?
Pelthos Therapeutics, Inc. quarterly revenues are $7.4M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Pelthos Therapeutics, Inc.'s net income of -$16.2M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Pelthos Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pelthos Therapeutics, Inc. is 9.07x versus 0.99x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTHSPelthos Therapeutics, Inc.9.07x -- $7.4M -$16.2M AGENAgenus, Inc.0.99x -- $30.2M $63.9M
-
Which has Higher Returns PTHS or GNPX?
Genprex, Inc. has a net margin of -219.26% compared to Pelthos Therapeutics, Inc.'s net margin of --. Pelthos Therapeutics, Inc.'s return on equity of -241.95% beat Genprex, Inc.'s return on equity of -900.4%.
Company Gross Margin Earnings Per Share Invested Capital PTHSPelthos Therapeutics, Inc.54.31% -$5.30 $61.7M GNPXGenprex, Inc.-- -$5.00 $767.8K -
What do Analysts Say About PTHS or GNPX?
Pelthos Therapeutics, Inc. has a consensus price target of $59.80, signalling upside risk potential of 125.07%. On the other hand Genprex, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 11060.71%. Given that Genprex, Inc. has higher upside potential than Pelthos Therapeutics, Inc., analysts believe Genprex, Inc. is more attractive than Pelthos Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTHSPelthos Therapeutics, Inc.5 0 0 GNPXGenprex, Inc.1 0 0 -
Is PTHS or GNPX More Risky?
Pelthos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genprex, Inc. has a beta of -0.771, suggesting its less volatile than the S&P 500 by 177.148%.
-
Which is a Better Dividend Stock PTHS or GNPX?
Pelthos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genprex, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pelthos Therapeutics, Inc. pays -- of its earnings as a dividend. Genprex, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTHS or GNPX?
Pelthos Therapeutics, Inc. quarterly revenues are $7.4M, which are larger than Genprex, Inc. quarterly revenues of --. Pelthos Therapeutics, Inc.'s net income of -$16.2M is lower than Genprex, Inc.'s net income of -$3.8M. Notably, Pelthos Therapeutics, Inc.'s price-to-earnings ratio is -- while Genprex, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pelthos Therapeutics, Inc. is 9.07x versus -- for Genprex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTHSPelthos Therapeutics, Inc.9.07x -- $7.4M -$16.2M GNPXGenprex, Inc.-- -- -- -$3.8M
-
Which has Higher Returns PTHS or LGND?
Ligand Pharmaceuticals, Inc. has a net margin of -219.26% compared to Pelthos Therapeutics, Inc.'s net margin of 10.18%. Pelthos Therapeutics, Inc.'s return on equity of -241.95% beat Ligand Pharmaceuticals, Inc.'s return on equity of 5.72%.
Company Gross Margin Earnings Per Share Invested Capital PTHSPelthos Therapeutics, Inc.54.31% -$5.30 $61.7M LGNDLigand Pharmaceuticals, Inc.89.7% $5.68 $1.4B -
What do Analysts Say About PTHS or LGND?
Pelthos Therapeutics, Inc. has a consensus price target of $59.80, signalling upside risk potential of 125.07%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $237.50 which suggests that it could grow by 28.47%. Given that Pelthos Therapeutics, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Pelthos Therapeutics, Inc. is more attractive than Ligand Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTHSPelthos Therapeutics, Inc.5 0 0 LGNDLigand Pharmaceuticals, Inc.5 0 0 -
Is PTHS or LGND More Risky?
Pelthos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.587%.
-
Which is a Better Dividend Stock PTHS or LGND?
Pelthos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pelthos Therapeutics, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTHS or LGND?
Pelthos Therapeutics, Inc. quarterly revenues are $7.4M, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $115.5M. Pelthos Therapeutics, Inc.'s net income of -$16.2M is lower than Ligand Pharmaceuticals, Inc.'s net income of $117.3M. Notably, Pelthos Therapeutics, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 88.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pelthos Therapeutics, Inc. is 9.07x versus 14.48x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTHSPelthos Therapeutics, Inc.9.07x -- $7.4M -$16.2M LGNDLigand Pharmaceuticals, Inc.14.48x 88.98x $115.5M $117.3M
-
Which has Higher Returns PTHS or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -219.26% compared to Pelthos Therapeutics, Inc.'s net margin of 13.19%. Pelthos Therapeutics, Inc.'s return on equity of -241.95% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital PTHSPelthos Therapeutics, Inc.54.31% -$5.30 $61.7M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About PTHS or PLX?
Pelthos Therapeutics, Inc. has a consensus price target of $59.80, signalling upside risk potential of 125.07%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Pelthos Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Pelthos Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTHSPelthos Therapeutics, Inc.5 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is PTHS or PLX More Risky?
Pelthos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock PTHS or PLX?
Pelthos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pelthos Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTHS or PLX?
Pelthos Therapeutics, Inc. quarterly revenues are $7.4M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Pelthos Therapeutics, Inc.'s net income of -$16.2M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Pelthos Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pelthos Therapeutics, Inc. is 9.07x versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTHSPelthos Therapeutics, Inc.9.07x -- $7.4M -$16.2M PLXProtalix Biotherapeutics, Inc.2.20x 24.89x $17.9M $2.4M
-
Which has Higher Returns PTHS or TVTX?
Travere Therapeutics, Inc. has a net margin of -219.26% compared to Pelthos Therapeutics, Inc.'s net margin of 15.59%. Pelthos Therapeutics, Inc.'s return on equity of -241.95% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.
Company Gross Margin Earnings Per Share Invested Capital PTHSPelthos Therapeutics, Inc.54.31% -$5.30 $61.7M TVTXTravere Therapeutics, Inc.89.46% $0.25 $403.3M -
What do Analysts Say About PTHS or TVTX?
Pelthos Therapeutics, Inc. has a consensus price target of $59.80, signalling upside risk potential of 125.07%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 18.57%. Given that Pelthos Therapeutics, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe Pelthos Therapeutics, Inc. is more attractive than Travere Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTHSPelthos Therapeutics, Inc.5 0 0 TVTXTravere Therapeutics, Inc.12 2 0 -
Is PTHS or TVTX More Risky?
Pelthos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.
-
Which is a Better Dividend Stock PTHS or TVTX?
Pelthos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pelthos Therapeutics, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTHS or TVTX?
Pelthos Therapeutics, Inc. quarterly revenues are $7.4M, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Pelthos Therapeutics, Inc.'s net income of -$16.2M is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Pelthos Therapeutics, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pelthos Therapeutics, Inc. is 9.07x versus 7.29x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTHSPelthos Therapeutics, Inc.9.07x -- $7.4M -$16.2M TVTXTravere Therapeutics, Inc.7.29x -- $164.9M $25.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 15.64% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 38.25% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.52% over the past day.
